A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy

Phase 1b/2a Study Investigating ATX-101 in Combination With Platinum-based Chemotherapy in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer

This is a Phase 1b/2a multicenter study, which consists of two parts: Part 1: the Phase 1b part of the study will investigate the safety of the combination of ATX-101 with carboplatin/gemcitabine (ACG) or carboplatin/pegylated liposomal doxorubicin (ACD). ATX-101 will be administered intravenously in three escalation cohorts: 20, 30, and 45 mg/m² according to a 3+3 design. In the case where 20 mg/m² is not tolerated, the dose can be de-escalated to 15 mg/m². Part 2: the Phase 2a part of the study will investigate the efficacy and safety of ACG or ACD. ATX-101 will be administered at the dose defined in Part 1 of the study. Each treatment combination (i.e., ACG or ACD) can start as soon as the ATX-101 MTD and /or RP2D has been established for the respective treatment combination in Part 1 of the study. Treatment will continue up to six cycles or until disease progression or unacceptable toxicity, participant withdrawal of consent, non-compliance, lost to follow-up, or withdrawal at the Investigators discretion, whichever occurs first.

A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy

Recruitment

Summary

Participation Requirements

Description

Tracking Information